PT-141 (Bremelanotide): Research Guide to the Sexual Health Peptide

PT-141, known by its generic name bremelanotide and marketed as Vyleesi, is a synthetic melanocortin receptor agonist that was FDA-approved in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It was developed by Palatin Technologies as a derivative of Melanotan II, specifically designed to target sexual arousal pathways while minimising the non-selective effects of its parent compound.

Unlike phosphodiesterase inhibitors (e.g., sildenafil) which act on peripheral blood flow, PT-141 works centrally in the brain by activating melanocortin-4 receptors (MC4R) in the hypothalamus. This makes it the first centrally-acting peptide approved for sexual dysfunction — a genuinely novel mechanism of action.

The peptide has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a cyclic heptapeptide closely related to Melanotan II but with modifications that improve MC4R selectivity.

Regulatory Note: PT-141/bremelanotide (Vyleesi) is FDA-approved in the US. It is NOT currently approved by the MHRA or EMA for use in the UK or EU. In these regions, any use would be off-label under medical supervision.

PT-141 works through a unique central nervous system mechanism:

Primary Pathway — MC4R in the Hypothalamus: 1. PT-141 is administered subcutaneously (abdomen or thigh) 2. The peptide crosses into the CNS and binds to MC4R in the medial preoptic area (MPOA) and paraventricular nucleus (PVN) of the hypothalamus 3. MC4R activation stimulates downstream oxytocin and dopamine pathways 4. These neurotransmitter cascades enhance sexual desire, arousal, and genital response 5. The effect is on *desire* (libido) rather than purely *mechanical* arousal

Why This Matters: - PDE5 inhibitors (Viagra, Cialis) work peripherally on blood flow — they help with erections but don't address desire - PT-141 works centrally on desire pathways — it can increase wanting and arousal - This makes PT-141 particularly relevant for HSDD, where the core problem is absent or low desire

MC4R Selectivity: Compared to Melanotan II, PT-141 has improved selectivity for MC4R over MC1R. This means: - Less melanogenic (tanning) effect - Reduced risk of mole changes - More targeted sexual arousal effect - Still some nausea (via central MC4R/area postrema)

Duration of Effect: - Onset: 30-60 minutes after subcutaneous injection - Peak effect: 1.5-3 hours - Duration: up to 12 hours in some studies - Half-life: approximately 2.7 hours

PT-141 has undergone extensive clinical evaluation, making it one of the most well-studied peptides:

RECONNECT Trials (Phase III): Two pivotal randomised, double-blind, placebo-controlled trials in premenopausal women with HSDD: - RECONNECT-1 (n=634): PT-141 1.75mg SC showed statistically significant improvement in desire (measured by FSDS-DAO and FSFI-D scores) vs placebo over 24 weeks - RECONNECT-2 (n=636): Confirmed findings with similar endpoints and statistical significance

Key Efficacy Results: - Approximately 25% of treated women reported meaningful improvement in desire vs 17% on placebo - The effect size was modest but statistically significant - Improvement was observed as early as 4 weeks - Effects were maintained over the 24-week treatment period

Male Studies: Earlier Phase II trials evaluated PT-141 for male erectile dysfunction: - Diamond et al. (2004): Showed PT-141 produced erections in men with ED, including those who did not respond to sildenafil - The male indication was not pursued to approval, though research continues

Safety Data from Trials: - Most common side effect: nausea (40% of treated vs 1% placebo) - Flushing (20%), headache (11%), injection site reactions (6%) - Transient blood pressure elevation (mean 3-6 mmHg systolic) - No melanoma signal in clinical trials - The FDA required a REMS (Risk Evaluation and Mitigation Strategy) due to blood pressure concerns

Approved Safety Information (from Vyleesi label): - Maximum recommended use: once per 24 hours, no more than 8 doses per month - Contraindicated in uncontrolled hypertension or known cardiovascular disease - Blood pressure monitoring recommended - May cause transient darkening of skin (hyperpigmentation), particularly of face, gums, and breasts - Nausea management: anti-emetics may be used prophylactically

Advantages Over Melanotan II: - Approved medication with defined safety data - More selective receptor profile - Controlled dosing (1.75mg autoinjector) - Manufactured to pharmaceutical standards - Post-marketing surveillance data accumulating - No significant melanoma signal

Remaining Questions: - Long-term safety data beyond 12 months is limited - The effect of chronic MC4R activation on appetite and weight is not fully characterised - Cardiovascular risk in populations not studied (postmenopausal women, men) remains to be established - Cost and access remain significant barriers

UK/EU Context: PT-141 is not currently available as an approved medicine in the UK or EU. Researchers and clinicians interested in this compound should be aware that any use would be unlicensed. The MHRA and EMA have not issued specific guidance on PT-141 use.